869365-97-9

Usage

Uses

Used in Pharmaceutical Research and Development:
(5-CHLORO-2-IODOPHENYL) 2,6-DIFLUOROPHENYL METHANO is employed as a key intermediate in the synthesis of new pharmaceutical compounds, leveraging its unique structural features to explore its potential in medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (5-CHLORO-2-IODOPHENYL) 2,6-DIFLUOROPHENYL METHANO is used as a building block for designing and developing innovative drugs, targeting various diseases and medical conditions. Its specific properties and interactions with biological systems need to be further investigated to fully understand and harness its therapeutic potential.
Used in Drug Discovery:
(5-CHLORO-2-IODOPHENYL) 2,6-DIFLUOROPHENYL METHANO serves as a valuable tool in drug discovery processes, where its chemical properties are assessed and optimized to create effective drug candidates with improved pharmacological profiles.
Used in Laboratory Settings:
For the comprehensive evaluation of its potential uses, (5-CHLORO-2-IODOPHENYL) 2,6-DIFLUOROPHENYL METHANO is utilized in laboratory experiments to study its chemical reactivity, stability, and interactions with biological targets, which are crucial for determining its suitability as a pharmaceutical agent.

InChI:InChI=1/C13H6ClF2IO/c14-7-4-5-11(17)8(6-7)13(18)12-9(15)2-1-3-10(12)16/h1-6H

Upstream product

• 869365-92-4 tert-butyl (4-chloro-2-(2,6-difluorobenzoyl)phenyl)carbamate 
• 18437-66-6 N-(t-butoxycarbonyl)-4-chloroaniline 
• 18063-02-0 2,6-difluorobenzoylchloride 
• 28910-83-0 (2-amino-5-chlorophenyl)-(2,6-difluorophenyl)methanone 

Downstream Products

• 869366-03-0 tert-butyl (3-(4-chloro-2-(2,6-difluorobenzoyl)phenyl)prop-2-yn-1-yl)carbamate 
• 1233025-91-6 (5-chloro-2-iodophenyl)(2-fluoro-6-methoxyphenyl)methanone 
• 869366-70-1 tert-butyl {3-[4-chloro-2-(2-fluoro-6-methoxybenzoyl)phenyl]prop-2-yn-1-yl}carbamate 
• 1028486-01-2 alisertib 
• 869367-33-9 8-chloro-4-[(dimethylamino)methylene]-1-(2-fluoro-6-methoxyphenyl)-3,4-dihydro-5H-2-benzazepin-5-one 
• 1028486-06-7 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate sodium salt 
• 869363-13-3 4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic acid 
• 869366-09-6 8-chloro-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one 
• 1393381-45-7 tert-butyl (1-(2-(4-((9-chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)benzamido)ethyl)piperidin-4-yl)carbamate 
• 1393381-46-8 N-(2-(4-aminopiperidin-1-yl)ethyl)-4-((9-chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)benzamide 
• 869366-10-9 8-chloro-4-[(dimethylamino)methylene]-1-(2,6-difluorophenyl)-3,4-dihydro-5H-2-benzazepin-5-one 

Relevant academic research and scientific papers

Small molecule with Aurora kinase degradation activity, preparation method and application thereof

The invention discloses a small molecule with Aurora kinase degradation activity, a preparation method and application thereof. According to the invention, 12 Aurora-A protein degradation agents basedon a PROTAC technology are obtained by using three E3 u

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective,

Bioorthogonal imaging of Aurora Kinase A in live cells

In living color: Aurora kinase A (AKA) was imaged in live cells using a bioorthogonal two-step reaction with a small molecule AKA inhibitor (see scheme) and a fluorescent reporter. The fluorescent molecule was localized to spindle poles and microtubules d

CRYSTALLINE FORMS OF SODIUM 4-{[9-CHLORO-7-(2-FLUORO-6--METHOXYPHENYL)-5H -PYRIMIDO[5,4-D][2]BENZAZEPIN-2YL]AMINO}-2-METHOXYBENZOATE

The present invention is directed to a compound of formula (Z): or a crystalline form thereof, or a solvate thereof; to a solid pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form

Compounds and methods for inhibiting mitotic progression

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treat